Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/53519
Title: Induction of G(2)/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells
Authors: Nicolini, Fabio
Burmistrova, Olga
Marrero, Maria Teresa
Torres, Fernando
Hernandez, Cristina
Quintana, Jose 
Estevez, Francisco 
UNESCO Clasification: 3205 Medicina interna
Keywords: Apoptosis
Flavonoids
Cell cycle arrest
Issue Date: 2014
Project: Evaluación de Potenciales Compuestos Antileucémicos. 
Journal: Molecular Carcinogenesis 
Abstract: Flavonoids are naturally occurring polyphenolic compounds which display a vast array of biological activities. In this study, we investigated the effects of tamarixetin on viability of human tumor cell lines and found that it was cytotoxic against leukemia cells and in particular P‐glycoprotein‐overexpressing K562/ADR cells. This compound inhibited proliferation in a concentration‐ and time‐dependent manner, induced apoptosis and blocked cell cycle progression at G2‐M phase. This was associated with the accumulation of cyclin B1, Bub1 and p21Cip1/Waf‐1, changes in the phosphorylation status of cyclin B1, Cdk1, Cdc25C and MPM‐2, and inhibition of tubulin polymerization. Moreover, cell death was found to be associated with cytochrome c release and cleavage of caspases and of poly(ADP‐ribose) polymerase, and completely abrogated by the free‐radical scavenger N‐acetyl‐L‐cysteine. The sensitivity of leukemic cells to tamarixetin suggests that it should be considered for further preclinical and in vivo testing.
URI: http://hdl.handle.net/10553/53519
ISSN: 0899-1987
DOI: 10.1002/mc.22055
Source: Molecular Carcinogenesis [ISSN 0899-1987], v. 53 (12), p. 939-950
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

50
checked on Dec 15, 2024

WEB OF SCIENCETM
Citations

45
checked on Dec 15, 2024

Page view(s)

89
checked on May 11, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.